20Jul 2021
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long‐term robust studies. To assess the malignancy risk in patients with secukinumab‐treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). This integrated safety analysis from both the secukinumab clinical trial programme and postmarketing safety surveillance data included any patient receiving at least one approved dose of secukinumab with a maximum of 5 years of follow‐up...

  • #dermatology

Like

Save

Share